Lataa...
Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C
The hepatitis C virus (HCV) leads to chronic liver disease and affects more than 2% of the world’s population. Complications of the disease include fibrosis, cirrhosis and hepatocellular carcinoma. Current therapy for chronic HCV infection, a combination of ribavirin and pegylated IFN-α, is expensiv...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2714653/ https://ncbi.nlm.nih.gov/pubmed/20161209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fvl.09.7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|